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Abstract: Large-scale functional genomics will require fast, high-throughput experimental tech-
niques, coupled with sophisticated computer algorithms for data analysis and experiment planning. In
this paper, we introduce a combined experimental-computational protocol called Structure-Activity Re-
lation by Mass Spectrometry (SAR by MS), which can be used to elucidate the function of protein-DNA
or protein-protein complexes. We present algorithms for SAR by MS and analyze their complexity.
Carefully-designed Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI TOF) and
Electrospray Ionization (ESI) assays require only femtomolar samples, take only microseconds per
spectrum to record, enjoy a resolution of up to one dalton in 106, and (in the case of MALDI) can
operate on protein complexes up to a megadalton in mass. Hence, the technique is attractive for
high-throughput functional genomics.
In SAR by MS, selected residues or nucleosides are 2H- 13C-, and/or 15N-labeled. Second, the
complex is crosslinked. Third, the complex is cleaved with proteases and/or endonucleases. Depending
on the binding mode, some cleavage sites will be shielded by the crosslinking. Finally, a mass spectrum
of the resulting fragments is obtained and analyzed. The last step is the Data Analysis phase, in which
the mass signatures are interpreted to obtain constraints on the functional binding mode. Experiment
Planning entails deciding what labeling strategy and cleaving agents to employ, so as to minimize
mass degeneracy and spectral overlap, in order that the constraints derived in data analysis yield a
small number of binding hypotheses.
A number of combinatorial and algorithmic questions arise in deriving algorithms for both Exper-
iment Planning and Data Analysis. We explore the complexity of these problems, obtaining upper
and lower bounds. Experimental results are reported from an implementation of our algorithms.
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1 Introduction
We wish to develop high-throughput algorithms for structural and functional determination of the
proteome. We hope that algorithms can be designed that require data measurements of only a few
key biophysical parameters, and these will be obtained from fast, minimal, cheap experiments. We
envision that, after input to computer modeling and analysis algorithms, structure and function of
biopolymers can be assayed at a fraction of the time and cost of current methods. Our long-range
goal is the structural and functional understanding of biopolymer interactions in systems of significant
biochemical as well as pharmacological interest. To this end we introduce a new method, called SAR
by MS (Structure-Activity Relation by Mass Spectrometry) for use in functional genomics.
SAR by MS is a combined experimental-computational protocol in which the function and binding
mode of DNA-protein and protein-protein complexes can be assayed quickly. Data from MALDI-TOF
MS (Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry) and ESI (Elec-
trospray Ionization) experiments are employed. Given a priori binding-mode and -region hypotheses,
computational methods are used to plan selective 13C- and 15N-labeling of proteins and DNA so that
subsequent MS (Mass Spectrometry) assays of cleaved complexes may distinguish among the set of
binding hypotheses. We investigate the complexity of computationally planning a labeling strategy to
yield unique mass signatures for cleaved fragments under each binding hypothesis.
In SAR by MS, a complex is first modeled computationally to obtain a set of binding-mode and
binding-region hypotheses. Next, the complex is crosslinked and then cleaved at predictable sites
(using proteases and/or endonucleases), obtaining a series of fragments suitable for MS. Depending
on the binding mode, some cleavage sites will be shielded by the crosslinking. Thus, depending on the
function, we will obtain a different mass spectrum. MALDI-TOF mass spectrometry techniques can
distinguish masses to within one dalton in 106 [18]. These techniques are so sensitive that reduced
vs. oxidized states of Cys residues can be distinguished in large proteins, although to obtain this
resolution, depletion of the naturally abundant 13C and 15N isotopes is often necessary [16]. We
can also manipulate the mass by 2H-, 13C-, and 15N-enrichment of oligonucleotide and amino acid
sequences. The enrichment can be selective (for example, all Leu and Ala residues in a protein can be
labeled using either auxotrophic bacterial strains or cell-free synthesis. DNA can also be selectively
labeled [12]). This paper reports on computational methods for analyzing the protein and DNA
sequences in order to plan selective labeling of the proteins and DNA so that subsequent MS assays
of the cleaved complexes are guaranteed to discriminate among the binding hypotheses. Hence, only
certain residue and nucleoside types will be isotopically labeled, and the labeling+cleavage plan should
result in no mass degeneracy — that is, the mass signature of the MS assay will be distinct, for every
pair of functional hypotheses. Such MS assays require only femtomolar sample amounts, and take
only microseconds per spectrum to record. At a qualitative level, SAR by MS is similar to traditional
molecular biology techniques using restriction enzymes and gels for DNA (or proteases and gels for
proteins). Both techniques require expression and purification of the biopolymer. However, the mass-
resolution, cycle time, and sample sizes are orders of magnitude more favorable using MALDI/ESI MS.
Therefore, these quantitative differences make SAR by MS an attractive method for high-throughput
functional genomics [17, 15]. The hope is that, with an appropriate algorithmic framework, the
technique could eventually scale to multi-protein complexes with masses up to hundreds of kilodaltons
(kDa). This paper presents initial steps in such a framework.
To begin an investigation of SAR by MS, we defer the problem of planning cleavage strategies,
assuming that a fixed library of proteases/endonucleases are employed. Generation of initial or a
priori binding mode hypotheses is not addressed in this paper, although we envision that docking
studies such as [10, 19] can be employed, together with homology searching, DNA footprinting, and
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Figure 1: MALDI-TOF mass spectra of an 18bp DNA duplex d(GACATTTGCGGTTAGGTC)∗-
d(CTGTAAACGCCAATCCAG). (Top) demonstrates the incorporation of 13C and 15N into the deoxyribose
and heterocyclic base of each nucleotide in the 18 bp oligonucleotide. (Bottom) displays the lower molecular weight
spectrum of an identical 18 bp oligonucleotide with natural isotopic abundance (12C and 14N). The rightmost peaks (>
5400) correspond to the DNA strands. Note the mass shift between the labeled and unlabeled oligos.
mutational analysis. When available, these hypotheses provide priors that restrict the set of fragment
interpretations. Assuming an arbitrary (possibly empty) set of initial binding-mode hypotheses, the
computational problem of planning the labeling strategies can be viewed as a geometric arrangement
problem in a high-dimensional configuration space. A number of interesting combinatorial problems
arise, and we derive upper and lower bounds. We explore an optimization strategy for SAR by MS, a
randomized approximation algorithm, a data analysis algorithm, and a novel probabilistic framework
for quantifying, predicting, and eliminating mass degeneracy through experiment planning. To do
this, we first formalize optimal experiment planning in such a way as to minimize mass degeneracy.
The optimization version of the problem appears to be difficult, and we prove that, under some fairly
natural conditions, an abstraction of the problem is NP-complete. We then consider subclasses of the
problem (feasibility vs. optimality) using a randomized approach. We consider tradeoffs between the
computational phases of experiment planning and data analysis. Although optimal experiment plan-
ning appears intractable, we show how, given a fixed experiment, the technique of spectral differencing
yields an output-sensitive polynomial-time algorithm for data analysis. Using spectral differencing,
we then derive probabilistic bounds on actual mass degeneracy from an analysis of the statistics of
hypothesis degeneracy. Finally, we present experimental studies for labeling and SAR by MS of the
protein-protein complex Ubiquitin Carrier Protein ubc9/Ubiquitin-Like Protein ubl1 (SMT3C). The
experiments support the theory. Some proofs have been omitted for reasons of space.
2 Experiment Planning
2.1 Experimental Setup
We now briefly review some aspects of the experiment design.
Resolution and Mass Range. MALDI and ESI produce gas-phase ions of biomolecules for their
analysis by MS. ESI produces a distribution of ions in various charge states, whereas MALDI yields
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predominantly singly-charged ions. Therefore, ESI spectra are correspondingly more complex. Smith
and coworkers [17] have shown how to reduce the charge state of ESI ions, to obtain greatly simplified
spectra in which fragments are manifested as single mass peaks (similar to MALDI). The decreased
spectral complexity afforded by charge reduction facilitates the analysis of mixtures by ESI MS. While
the mass limit for MALDI is about a megadalton, charge-reduction TOF ESI has a mass limit of
about 22 kDa. However, ESI appears to respect weak covalent interactions (such as the hydrogen
bonds) [15], whereas complexes for MALDI must be covalently crosslinked.
Crosslinking. Crosslinking (the covalent linking of a multimer) is most commonly used for DNA-
protein complexes. For protein-protein complexes, a residue can be mutated to a photoreactive amino
acid such as p-benzoyl L-phenylalanine (BPA) [11]. After exposure to UV light, the complex is
crosslinked. Below 22 kDa, one alternative to crosslinking is to use ESI MS, which seems to respect
hydrogen bonds so that bound fragments will have a spectral peak at the sum of their masses [15].
Stable Isotopic Labeling. Uniform and selective labeling of proteins is a standard molecular
biology protocol (e.g., for heteronuclear protein NMR). Until recently, the methodology for the uniform
and selective labeling of DNA needed to perform these MS experiments was not available. However,
recent advances in the enzymatic synthesis of 13C and 15N-labeled DNA in milligram quantities have
the potential to revolutionize the NMR and MS analysis of nucleic acids (see Fig. 1 and [12]).
2.2 Experiment Planning as an Optimization Problem
The problem of planning labeling can be viewed as an optimization problem. We call this problem om-
sep for Optimal Mass Spectrometry Experiment Planning. Consider the simplified problem
of determining the binding mode of a protein-protein complex using 13C- and 15N-selective labeling
followed by MS. For simplicity, we will consider only one, fixed cleavage agent, the protease Trypsin,
which cleaves the peptide bond following Lys and Arg residues. Given (any) two fragments k and l,
we wish to plan a labeling such that their masses are distinct whenever k = l. That is∑
i∈R
nki(mi + xi) =
∑
i∈R
nli(mi + xi), (1)
where R is the set of residues {Ala, Arg, Asn, Asp,. . .}, mi is the unlabeled monoisotopic integer mass
of residue type i, xi is the additional mass of residue i after labeling, and nki (resp. nli) is the number
of residues of type i in fragment k (resp. l). Note that xi ∈ {0, ĉi, n̂i, ĉi+ n̂i}, where ĉi is the additional
mass after labeling residue type i with 13C and n̂i is the additional mass after labeling residue type i
with 15N. Thus, for example, for i = 2 (Arginine), m2 = 156, ĉ2 = 6, and n̂2 = 4. Now, let
Nkl = (nk1 − nl1, nk2 − nl2, nk3 − nl3, . . .), Ckl = Nkl · (m1, m2, . . .), X = (x1, x2, . . .). (2)
Then Eq. (1) can be written as the constraint
fkl(X) = 0, where fkl(X) = Nkl ·X +Ckl. (3)
We have a constraint of the form Eq. (3) for every pair of distinct fragments k and l. Whenever
a constraint fkl is violated, we obtain mass degeneracy (two fragments with the same mass). Our
goal is to find a labeling X that minimizes the amount of mass degeneracy. To do this, we attempt
to minimize the number of constraint violations of the form fkl(X) = 0. An exact solution to this
optimization problem would find the best labeling—that is, the labeling that minimizes the number
of constraint violations, and hence the “amount” of mass degeneracy. An approximate solution would
come “close”—for example, within an (1 + ε) factor of the minimum, for some small ε.
The constraint (3) can be expressed as a disjunction of inequality relations (that is, < or >).
Inequalities can also enforce peak separation in the spectrum. For example, to ensure a peak separation
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of at least δ, Eq. (3) becomes the disjunction1 fkl(X) > δ or fkl(X) < −δ.
Computational experiments that we implemented to search for the minimum-degeneracy labeling
suggested that the problem may be difficult to solve efficiently. In particular, the initial heuristic
search algorithm we implemented could run for a very long time without finding a labeling. This
motivates a careful investigation of the complexity, and the need for better algorithms.
Basic Combinatorics. A protein or protein-protein complex is digested by a protease, yielding
a set of fragments. Due to incomplete digestion or shielding, there may be many more potential
fragments than observed fragments. In particular, we consider here the case of sequential unions,
where two or more sequential fragments remain joined rather than being cleaved at the anticipated
cleavage site. Mass degeneracy results when the masses of two fragments are indistinguishable with
respect to the resolution of a particular spectrum. Finally, a selective labeling scheme uses different
isotopes in specific amino acids (e.g. Arg with 15N instead of 14N) to affect the resulting mass spectrum.
Let p be the number of fragments after crosslinking and Trypsin cleavage, and n = |R| be the size
of the set R, that is, the number of residue types. Then the number of constraintsm of type Eq. (3) is
O(p2). Although in theory n is bounded by a constant of about 20, exhaustive search is not possible,
since there are approximately 4n different labeling schemes (8n with 2H-labeling). We begin by treating
n and m as parameters that measure the input complexity of the problem. To bound the number of
fragments, p, we consider a 2-protein complex, in which each protein has s cleavage sites. Each site
can (potentially) be shielded from cleavage when it is spatially near the protein-protein interaction
site. The regions of the primary sequence between adjacent cleavage sites are called segments. Protein
1-fragments are formed of sequential unions of segments.
Example: If a peptide of 20 residues has cleavage sites 5 and 10, then the segments are (1,5), (6,10),
and (11,20). The 1-fragments are these 3 segments, plus (1,10), (1,20), and (6,20). Thus, a protein
with s cleavage sites can have O(s2) 1-fragments.
When two interacting proteins are crosslinked and cleaved, a 2-fragment may be formed by the
binding of one 1-fragment from each protein. The mass spectrum will then exhibit a peak at the mass
of the 2-fragment. We take this peak as evidence that the two constituent 1-fragments are implicated in
the active site of the protein-protein complex. In particular, such a 2-fragment is formed by crosslinking
the active sites, followed by cleavage on each protein strand. Thus we obtain p = O(s4) 2-fragments. A
fragment is defined to be any i-fragment (i = 1, 2). Now, in any MS experiment, we will only see peaks
from some of these fragments. These are because the fragments may represent competing (mutually
exclusive) hypotheses about binding modes. However, in terms of experiment planning, we must be
able to distinguish between any pair of hypothesis. Hence, we have m = O(p2) = O(s8) constraints.
Example: Consider the interaction of the 1-fragments {g1, g2, g1∪ g2} of one protein with 1-fragment
h of another. One binding hypothesis is that h will bind and shield the cleavage site g1/g2. This
hypothesis is encoded as the single 2-fragment g1 ∪ g2 ∪ h. Let m(g1) denote the mass of g1, etc. If
the hypothesis is false, we should see a mass spectrum with three peaks, {m(g1), m(g2), m(h)}. If it is
true, we should see a single peak, at m(g1) +m(g2) +m(h).
Our goal is to use selective labeling to force the fragment masses to be distinct.
It is clear that not all 1-fragment/1-fragment interactions are possible. Some may be excluded
based on 1-fragment length. For example, it may be impossible to shield two cleavage sites that are
t-apart with a single u-mer if u 
 t. Such reasoning requires careful modeling: for example, the longer
strand may be heavily kinked. Computational methods can be employed to form hypotheses about
binding modes. These should greatly help the combinatorics, since an experiment would only need to
distinguish the fragments identified by hypothesis, and could allow degeneracy in unrelated fragments.
1In practice, mass degeneracy is given in parts per thousand, not as constant. We can encode this by making δ
dependent on k and l, and rewriting this equation as fkl(X) > δkl or fkl(X) < −δkl.
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In this model, predictions of docking and binding would be made on the computer, and labeling+MS
would be performed as a way of screening these hypotheses to test which are correct.
Lower Bounds. Experimentally, omsep appears difficult to solve efficiently. omsep is an instance
of the NP-complete problem Minimum Unsatisfying Linear Subsystem (muls) [5, 13, 7, 6, 8, 14,
3]. We show that a variant of omsep is NP-complete: (the proof is in the appendix)
Lemma 1 omsep using only 13C selective labeling is NP-complete.
2.3 Satisficing Instead of Optimizing
Since the optimization problem omsep in Sec. 2.2 is intractable, we pursue a different approach.
Instead of using only one labeling, we investigate experiment plans with several different labelings.
First, we explore a necessary condition for experiment planning. Next, we present a stronger, sufficient
condition and then discuss how a practical, necessary and sufficient condition may be obtained.
2.3.1 A Necessary Condition
In the Necessary Condition approach, we label the proteins in several different ways, to produce
several samples. MALDI or ESI MS is performed on each sample. We do not require that each pair
of fragments have distinct masses in every labeling-MS experiment. However, we do require that for
every pair of fragments, there exists some labeling in which their masses are distinct.2
Let L be a set of labelings. L may be represented by a set L = {1, 2, . . .} where each i is a point
of the form X in Eq. (2). For a pair of fragments k and l, and a labeling  ∈ L, we can ask whether
their masses are distinct under labeling . That is: fkl() = 0? The constraint fkl is given in Eq. (3).
Hence, our necessary condition is:
Feasibility Condition: Find a set of labelings L = {1, 2, . . .} such that for every pair of fragments
k and l, either k = l or there exists some labeling Xkl ∈ L, such that fkl(Xkl) = 0. We call L a
Feasible Set of Labelings.
The Feasibility Condition can be converted into an optimization problem—for example, minimizing
the number of experiments or the number of different amino acids labeled in each experiment. Let us
focus on the first. The Feasibility Condition requires that we find a set of labelings such that for every
pair of fragments, there is at least one labeling in which the pair is not mass degenerate. If there are
p fragments, the feasible labeling set L (when it exists), could be large, which would not be practical.
Obviously, the smaller p is, the better. This leads to the optimization version of our problem, which
can be given as follows. Let |L| be the size of L (the number of labelings required):
Optimization: Minimize the size |L| of the Feasible Set of Labelings L.
It follows from Lemma 1 that the optimization version of this problem is NP-hard. Therefore,
we explored how feasibility (without optimality) could be computed (i.e., to obtain a “small” number
of unsatisfied constraints) using the primary sequences for Ubiquitin Carrier Protein (ubc9) and
Ubiquitin-Like Protein (ubl1) under trypsin cleavage, with the following algorithm:
Randomized Algorithm. First, a random labeling is chosen. If two trypsin-cleaved fragments
are mass-degenerate under this labeling, then another labeling is randomly chosen. This process is
repeated until, for every pair of distinct fragments, there exists at least one labeling in which the pair
has distinct masses.
The randomized algorithm merely checks the necessary condition. Somewhat remarkably, in prac-
tice, this results in satisfying much stronger conditions (see below). One of our goals is to elucidate
why this is so. We believe that such an algorithm can yield efficient labeling strategies. In Sec. 2.4
2Note that fragments whose primary sequences are permutations of one another cannot be distinguished by label-
ing+MS.
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we report on an implementation using this idea. Using this algorithm, we discovered that ubl1 re-
quires only one labeling. The minimum |L| for ubc9 is not known, but 5 labelings suffice to solve the
feasibility problem for this protein. Hence |L| ≤ 5 suffices for ubc9, and |L| = 1 suffices for ubl1.
2.3.2 Necessary vs. Sufficient Conditions
We say that ambiguity occurs when, in a data spectrum, it is impossible to assign each mass peak to
a unique fragment, due to mass degeneracy. This makes it impossible to infer which fragment caused
each peak, and therefore we cannot infer which fragments are experimentally present.
Claim 2 The Feasibility Condition in Sec. 2.3.1 is worst-case necessary and sufficient to eliminate
ambiguity in the case |L| = 1.
Claim 3 For |L| > 1, the Feasibility Condition is necessary but not sufficient.
Proof: Necessity is definitional. We show it is not sufficient. Suppose L = {X1, X2}. Let k, g1, g2 be
fragments, and let ψi(k) denote the mass of fragment k in labeling schemeXi. Suppose ψ1(k) = ψ1(g1),
ψ1(k) = ψ1(g2), ψ2(k) = ψ2(g2), and ψ2(k) = ψ2(g1). Then the Feasibility Condition holds, but it is
impossible to assign the k-g1 or k-g2 peaks. In particular, we cannot guarantee that k’s presence or
absence can be inferred.
Claim 4 A Sufficient Condition for |L| > 1 is given as follows: Find a set of labelings L such that
for every fragment k, there exists a labeling Xk ∈ L such that, for every fragment g = k, fkg(Xk) = 0.
In practice, the sufficient condition in Claim 4 is much stronger than we need. We give some
intuition as to why. First, the absence of a peak in one labeled spectrum can disambiguate a potential
mass degeneracy in another. For example, in the proof of Claim 3, if fragment g1 does not occur, then
the peak ψ2(g1) will be missing if ψ−12 (ψ2(g1)) is a singleton. In this case, the k-g1 peak in labeling
X1 can be unambiguously assigned to k. Thus, the sufficient condition does not take into account the
expected information content of negative evidence. Since roughly s4 − s fragments will not occur in
any experiment, we expect to find a great deal of negative evidence. In Sec. 3, we incorporate negative
evidence into the data analysis phase.
Second, the necessary condition (Feasibility in Sec. 2.3.1) imposes O(s8) constraints on O(s4)
fragment hypotheses. However, in any physical experiment, only O(s) fragments will appear. These
fragments are so constrained by the O(s8) clauses of the necessary condition, that mass degeneracy is
rare. The randomized experiment planning algorithm described above can be viewed as “satisficing
a necessary condition,” as opposed to optimally satisfying a necessary condition (which would mean
minimizing |L|), or satisfying a worst-case sufficient condition like Claim 4 (which would be so pes-
simistic as to demand a very large number of experiments). Our goal is to minimize or reduce the
ambiguity from mass degeneracy in an O(s)-size sample F∗ that is selected “randomly” from a larger,
O(s4)-sized set F of fragment hypotheses, given statistics on the mass degeneracy in F . Below, and
in Sec. 4, we quantitate these observations by modeling the statistical properties of mass degeneracy.
Statistics of Mass Degeneracy. A variety of statistical measures of mass degeneracy are
possible. For example, let k ∈ F be a fragment and ψi : F −→ N be as above. We define c(k, i) =
|ψ−1i (ψi(k))|, to be the number of fragment hypotheses potentially confusable with k in experiment
Xi. Then given a set of fragment hypotheses F , we say that a labeling L is (β, η)-good if the set
{k ∈ F | ∀Xi ∈ L, c(k, i) > β} has fewer than η elements. Hence, in a (β, η)-good labeling plan, the
number of fragment hypotheses that are mass degenerate more than β is bounded above by η. The
Sufficient Condition of Sec. 2.3.2 is equivalent to (1, 1)-goodness. When a labeling plan is (β, η)-good
we can give the experimentalist a guaranteed upper bound on the amount of mass degeneracy she
will encounter. This worst-case measure is still too strong in practice. In Sec. 4, we explore a weaker
measure, in which probabilistic bounds on actual mass degeneracy (in F∗) are derived from an analysis
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of hypothesis degeneracy (using the statistics of F ). We also describe computational experiments that
support the theory. Derivation of this data-driven necessary and sufficient condition for probabilistic
mass degeneracy in Sec. 4 depends on the data analysis technique of spectral differencing, which we
discuss in Sec. 3.
2.4 Experimental Results
The randomized algorithm (Sec. 2.3.1) quickly identified isotopically-labeled mass spectrometry ex-
periments to disambiguate fragments in two example proteins. The algorithm was run for 1000 trials,
with each trial identifying a set of experiments that disambiguate the fragments. A minimal-sized
experiment set (not necessarily unique) was chosen from this group. Two fragments were considered
ambiguous if their masses differed by less than one part per thousand. The computation required
about three minutes of real time on a 400MHz Pentium II machine, running interpreted Scheme code.
Results for the proteins ubl1 [2] and ubc9 [1] are given in Table 1. Fragments of ubl1 can be dis-
ambiguated with one correctly-chosen isotopic labeling. Fragments of ubc9, however, require a set of
labelings—the first labeling leaves 18 ambiguous pairs, of which only 10 are ambiguous with respect
to the second labeling, and so forth. In Sec. 4 we calculate a probabilistic measure of how well these
planned experiments are expected to eliminate mass degeneracy (see P(interp) in Table 1).
For the ubl1-ubc9 complex, the program identifies 120 fragments for ubl1 and 276 fragments for
ubc9, and thus 33516 fragments for the cross product. It then identifies 434241 mass-degenerate pairs
in this set of fragments. This is far too many pairs for a small set of experiments to disambiguate,
underscoring the importance of computational modeling and prediction of feasible fragments in the
complex. A reasonable set of priors would restrict the number of functional hypotheses to a few hun-
dred. Our experiments are evidence that SAR by MS can discriminate among hundreds of hypotheses,
which should be sufficient for many complexes of interest.
3 Data Analysis
Optimal experiment planning (Sec. 2.2), attempts to carefully design the experiments so that
the data analysis devolves to a table-lookup. The process is designed to minimize ambiguity in
fragment hypothesis interpretation. Without experiment planning to minimize mass degeneracy, the
data analysis may yield ambiguous results (i.e., competing fragment and binding-mode hypotheses).
Since optimal experiment planning appears difficult, in this section, we investigate an alternative
approach, obtaining polynomial-time algorithms when some potential ambiguity can be tolerated.
A continuum of design tradeoffs is possible between planning and analysis. To explore this idea,
we picked a point near the other end of the design spectrum, in which we assume that the experiment
plan (labeling+cleavage) is given a priori, and the data analysis algorithm reports on the hypotheses
than can be inferred from the collected spectra. The hypotheses will typically not be unique, since the
experiment was not optimally planned. Our algorithm investigates the power of spectral differencing.
We show that, for a fixed plan, spectral differencing analysis can be done efficiently (polynomial time).
3.1 Spectral Differencing
Trained spectroscopists interpret mass spectra using a technique called spectral differencing, in
which two spectra from different labelings of a complex (but using the same cleavage agents) are
compared. For example, a peak in an unlabeled (natural isotopic abundance) mass spectrum will shift
to a higher mass in a selectively 15N-labeled spectrum (cf. Fig. 1). When peaks can be tracked across
spectra, the corresponding mass shifts can be used to infer which fragment generated the peak. In
this vein, we now consider the simpler problem of data interpretation given a labeling and cleavage
plan (for example, the plan may have been selected in a randomized strategy, such as in Sec. 2.3.1).
Given a complex and a fixed cleavage agent, let Si be a mass spectrum, represented as a set of
masses (at observed peaks) {s1, s2, . . .}, under labeling scheme Xi. Xi = {x1, x2, . . .} is a vector of
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labels as in Eq. (2). Let φi(s) be the set of fragments which could have produced peak s: φi(s) =
{k ∈ F | s ≈ ψi(k)}, where ψi(k) is the mass of fragment k under Xi. Spectral differencing then
identifies pairs of peaks in two different spectra S1 and S2 such that the same fragment could have
caused both peaks. Let F be the set of all possible fragments. We define the set of interpretations of
the mass shift (s1, s2) for peaks s1 ∈ S1 and s2 ∈ S2 as φ1(s1) ∩ φ2(s2). Due to mass degeneracy, s1
in spectrum S1 could have multiple explaining fragments k ∈ φ1(s). However, each such k must also
have a peak s2 in spectrum S2 with k ∈ φ2(s2) in order to be consistent with the spectral difference.
This approach uses negative evidence to rapidly prune the number of fragments being considered.
We now develop a fast algorithm for spectral differencing. The difference spectrum of S1 and S2 is
obtained from the Minkowski difference S2  S1 = {s2 − s1 | s2 ∈ S2, s1 ∈ S1} as follows. In general,
there will be constraints on which pairs of peaks in S1×S2 can participate in the difference spectrum.
In the example above, X1 = 0 (i.e., S1 is unlabeled) andX2 contains only positive and zero increments.
This means that all mass shifts must be between 0 and some maximum value t that depends on the
primary sequence (for example, if all Arginine residues are labeled with 15N, then the upper bound
t for the mass shift of a fragment is given by the maximum number of Arg residues in any fragment
times n̂2 = 4). There will be a lower bound l as well (for example, l = 0 if there is any Arginine-free
fragment), and in general l and t can be made tighter by varying as functions of s1. Hence, we define
the difference spectrum as
D(S1, S2) = {(s1, s2) ∈ S1 × S2 | s2 − s1 ∈ [l(s1), t(s1)]}. (4)
Now, suppose a peak s ∈ S1 is caused by a fragment fk. Following Eq. (2), we get
s = N(fk) · (M +X1). (5)
Hence, N (fk) is simply the vector encoding the counts of each residue type. Now, because of mass
degeneracy, we may also have other fragments f2, f3, etc. that can cause s. That is, s = N (f2) · (M +
X1), s = N (f3) · (M+X1), as well. Suppose (s, r) ∈ D(S1, S2), i.e., r is a candidate match for s across
spectra. We say a fragment fk explains the mass shift (s, r) when Eq. (5) holds and
r − s = N(fk) · (X2 −X1). (6)
Let F be the set of all possible fragments. We define the set of interpretations of the mass shift (s, r)
as I(s, r) = {fk ∈ F | Eqs. (5) and (6) hold}. Finally, given two spectra S1 and S2 with labelings
X1 and X2, the set I(D(S1, S2)) represents the fragment hypotheses consistent with the difference
spectrum.
We now develop an output-sensitive algorithm for computing the consistent fragment hypotheses
I(D(S1, S2)). Consider a dimeric protein complex P with n residues. Given a cleavage agent γ, we
obtain a crosslinked and cleaved system P(γ), containing both 1- and 2-fragments. While the set of
possible fragments that could make up P(γ) is large (O(n4)), in any particular P(γ) we will see only
O(n) 1-fragments (see Sec 2.2). A priori, there could be O(n2) 2-fragments, but we do not expect it is
geometrically feasible for every pair of 1-fragments to crosslink. Therefore, we expect to observe only
O(n) 2-fragments. Hence, we expect the size c of the crosslinked and cleaved system P(γ) to be O(n).
For larger proteins, we find that in practice, the mass values are only accurate to some uncertainty
bound ε. To cope with this uncertainty, we employ 1D range-searching:
Claim 5 Suppose we are given two spectra S1 and S2 of a crosslinked and cleaved system P(γ) with
labelings X1 and X2 (respectively), together with a tolerance ε representing the resolution of the spectra.
Then the fragment hypotheses consistent with the toleranced difference spectrum can be computed in
output-sensitive time O(c2 log n) where c is the size of P(γ), using O(n4 logn) preprocessing time.
Proof: To compute I(D(S1, S2)), we store, for each fragment f , the interval [z(f)− ε, z(f) + ε] and





















Figure 2: Interpretability of randomly planned sets of 1, 2, and 5 labelings (left to right), for ubl1 (graphs 1-3) and
ubc9 (graphs 4-6). Each bar indicates how many sets, out of 100, have the given probability of interpretability.
time O(n4 logn). Given a potential mass shift, we perform a lookup in the tree in time O(logn). The
size of the difference spectrum is bounded above by the size of the Minkowski sum S2  S1, which is
O(c2). Thus, we do O(c2) lookups in time O(c2 logn). For each non-empty lookup, we also check in
O(1) time that Eq. (5) holds.
Corollary 6 Spectral differencing under uncertainty can be extended to analyze spectra from d selec-
tive labeling schemes, with O(dc2 log n) running time and O(dn4 logn) preprocessing time.
Although the O(n4 log n) preprocessing time is nontrivial, we envision it could be done in parallel
with the wetlab molecular biology (selective labeling), which can take on the order of days. Wetlab
expression and purification times will be similar in MS, NMR, Xray, or gel studies. However, taking
the MALDI or ESI mass spectrum will be orders of magnitude faster than the the post-expression
phases of NMR, Xray, or gel methods. After preprocessing, the O(c2 logn) computational lookup
phase should be very fast, on a similar timescale to MS recording.
4 Probabilistic Mass Degeneracy
The data analysis techniques discussed in Sec. 3 correlate information among multiple spectra
from different labelings, overcoming mass degeneracy by eliminating fragment hypotheses that are not
consistent with all spectra. Since there are a large number of fragment hypotheses (O(s4)) but only a
small number of observed peaks (O(s)), it is likely that many potential ambiguities can be resolved by
spectral differencing, given experimental data. The experiment planning sufficient condition (Claim 4)
operates without experimental data, assuming the worst case, and thus may be far too strict in
practice. This section derives probabilistic measures that approximate the likelihood that spectral
differencing will be able to resolve potential ambiguities. In particular, we distinguish correct and
incorrect fragment hypotheses as those that respectively do and do not correspond to peptides existing
in the sample. We then address the following question:
Claim 7 Spectral differencing fails to eliminate all incorrect fragment hypotheses if and only if there
exists an incorrect fragment hypothesis k, such that, for each labeling X ∈ L, there exists a correct
fragment hypothesis lX such that fklX (X) = 0.
Negating the condition in Claim 7, we learn when spectral differencing can eliminate all incorrect
fragment hypotheses. Note that this does not mean that all peaks will be uniquely assigned, since
the correct fragment hypotheses might be mass degenerate. However, it does satisfy our objective of
eliminating incorrect hypotheses.
4.1 Probabilistic Framework
To compute the likelihood of satisfying Claim 7 with a given set of labelings L, first impose a
distribution on the a priori probability that a fragment is correct. For simplicity, we assume here that
this is uniform: the expected number of correct hypotheses p∗ = E(|F ∗|) divided by the number of
possible hypotheses p = |F |. An upper bound can be derived by setting the expected number of correct
hypotheses p∗ to the number of fragments in the completely-digested protein. Any available modeling
assumptions can be incorporated into this distribution. In the derivation below, let ℘ = p∗/p.
We say a particular incorrect fragment hypothesis f appears in a particular experiment i unless all





13C-labeled 15N-labeled χ P(interp)
unlabeled unlabeled 27 0.021
NDQEHILKSTWV RCQHKMSTWYV 18 0.88
QGISWV ACQEGIKPY 10 0.99
ANDCEGHILS RCQGILMFPSWY 3 0.9998
ARNQEHKMSV ACQGLMWY 1 0.99999
DCQEILSW ANEGLKMFTWY 0 0.9999997
Table 1: Isotopically-labeled experiment planning results from the randomized algorithm. (Left) Single experiment
disambiguating fragment masses for ubl1. (Right) Sequence of experiments collectively disambiguating fragment masses
for ubc9. χ = number of remaining ambiguities. P(interp) is the probability that spectral differencing can eliminate all
incorrect fragments (Eq. (7)).
ψ−1i (ψi(f)) denote the conflict set (mass-degenerate fragments) of fragment f in experiment i, and
c(f, i) = |C(f, i)|. Then P (appears(f, i)) = 1− ∏
g∈C(f,i)
P (incorrect(g)) = 1− (1− ℘)c(f,i).
We say a particular incorrect fragment hypothesis f is eliminatable unless for all experiments i ∈ L,
f appears in i. Hence, P (eliminatable(f, L)) = 1 − ∏
i∈L






An incorrect fragment hypothesis f is uneliminatable when it is not eliminatable.
Finally, a set of labelings L is interpretable (Claim 7 is unsatisfied) if for all fragments f , f is not
both incorrect and uneliminatable.
Since P (interpretable(L)) =
∏
f∈F













Eq. (7) defines an interpretability metric for a set of labelings, indicating how likely it is that spectral
differencing will be able to eliminate all incorrect fragment hypotheses.
4.2 Experimental Results
We have tested the interpretability metric for the proteins in Section 2.4. Table 1 gives the in-
terpretability metric for both the unlabeled protein and the labeled protein. Note that the metric
converges to 1.0 with the addition of more labelings distinguishing more mass-degenerate pairs, demon-
strating the power of spectral differencing to combine information across experiments. In the extreme
case, when the sufficient condition (Claim 4) is satisfied (as with the planned labeling for ubl1), the
interpretability probability equals 1.0.
We have also studied the ability of random labeling sets to satisfy the interpretability condition.
Figure 2 shows histograms of the metric for sets of 1, 2, and 5 random labeling sets, with 100 samples
generating each histogram. As these plots illustrate, the interpretability metric provides a concrete
indication that ubl1 is easier to disambiguate than ubc9. Randomization is able to effectively sample
the space of labelings, and our planning algorithm can find sets of labelings that, with high probability,
spectral differencing will be able to interpret. Fig. 2 shows empirical evidence that the Randomized
Algorithm (Sec. 2.3.1) and the interpretability metric (Eq. (7)) are mutually beneficial, and may be
combined in a package for experiment planning to probabilistically eliminate mass degeneracy.
5 Conclusions
MALDI and ESI MS are fast experimental techniques requiring subpicomolar sample sizes. They
are therefore attractive for high-throughput functional genomics studies. However, while much faster,
the information extracted is rather minimalist compared to NMR or Xray crystallography. There-
fore, a large burden is placed on the algorithmic problems of experiment planning and data analysis
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for SAR. In this paper, we explored the complexity of SAR by MS. We investigated optimal experi-
ment planning (omsep) where the objective is to minimize mass degeneracy, and showed that, under
fairly natural conditions, a 13C-only variant of this problem is NP-complete. We then explored more
tractable subclasses, tradeoffs, and implementation experiments. If we require only feasibility instead
of optimality, we can develop a randomized algorithm that processes across spectra to eliminate mass
degeneracy. While this technique appears to be efficient, it does not minimize the number of experi-
ments. We implemented and tested the algorithm in a study of the protein-protein complex Ubiquitin
Carrier Protein/Ubiquitin-Like Protein (SMT3C).
On the other hand, if we are given an a priori experiment plan, we can use the information
content in the difference spectra to track mass shifts. This more sophisticated data analysis can
be done efficiently, and we provide an output-sensitive, polynomial time algorithm for the spectral-
differencing data analysis. Using spectral differencing, we then derived probabilistic bounds on actual
mass degeneracy using an analysis of the statistics of hypothesis degeneracy. This let us quantitate
the effectiveness of the randomized algorithm. Computational experiments on the SMT3C system
support our construction of a data-driven necessary and sufficient condition (Eq. (7)) for probabilistic
mass degeneracy.
The algorithms and bounds we explored represent first steps in a computational framework for
SAR by MS. We believe this will be a dynamic and fruitful area for future research.
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A Lower Bounds (Proof of Lemma 1)
This proof has been relegated to the appendix for reasons of space.
We wish to show that omsep is a difficult problem, by showing that it is NP-complete. There are
several “difficulties” in proving a real biological or biochemical problem is NP-hard. First, the number
of amino acids is fixed at 20 and the maximum “reasonable” size of a protein is also fixed by nature,
so in a complexity-theoretic sense all problems can be solved in constant time. Of course this doesn’t
capture the observed complexity of these problems. Thus, we will allow the number of amino acids
and the length of the protein to be variables. In the case of protein size, this is a standard abstraction
that has been used elsewhere. It is less standard for the number of amino acid types, but we believe
the “420” combinatorial argument in Sec. 2.2 justifies this abstraction.
There is another way in which an NP-completeness proof may fail to capture true biochemical
problems. A biochemical problem may have some restrictions on the possible input parameters that
don’t arise in other types of problems. For example, if one is trying to show that a problem with
a non-negative input parameter x is NP-hard, it is sufficient to show that it is NP-hard when x is
restricted to be 0 or 1. However, this might not be sufficient for a biochemical problem in which x
might be some physical parameter, such as mass, and restricting it to be say, 0 or 1, leaves you with
a set of problems that are not physically realizable or interesting. Thus the challenge, roughly, is to
show that set of instances which are hard has a non-empty intersection with the set of problems that
arise biochemically.
The following problem BIN FLS =, (Feasible Linear System with {0, 1} variables and = con-
straints), is known to be NP-complete [3, 4]:
Problem name: BIN FLS =
Input: aij ∈ Q, i = 1, . . . , n, j = 1, . . . , m and bi ∈ Q, i = 1, . . .n.
Problem definition: Does there exist xj ∈ {0, 1}, j = 1, . . . , m such that
m∑
j=1
aijxj = bi, i = 1, . . . , n (8)
See [5, 13, 7, 6, 8, 14] for other related work on BIN FLS.
Lemma 8 For every instance of BIN FLS =, and any set of ri, with the size of each ri bounded by a
polynomial in the original input size, i = 1, . . .n, there is an equivalent instance with n+m variables
and 2n inequalities, in which n of the right hand sides are ri, i = 1, . . .n, and n are 0.
Proof: Let the n additional binary variables be called y1, . . . , yn. Then we form the following
system of 2n inequalities. Consider the following modified problem:
m∑
j=1
aijxj + (ri − bi)yi = ri, i = 1, . . . , n
yi = 0, i = 1, . . . , n
Since in any satisfying assignment, all the yi’s must be 1, this instance is algebraically equivalent to
the BIN FLS = one.
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Lemma 8 tells us we have the freedom to choose any rational right hand sides; in particular we
can choose them as functions of biochemical parameters and still have an NP-complete problem.
We now introduce an variant of omsep, in which only 13C selective labeling is permitted. We call
this problem 13C-omsep-sat:
Problem name: 13C-omsep-sat
Input: m amino acids z1, . . . , zm, each with cj carbons and mass mj (cj > 0 and mj > 0 for proteins).
n constraints, where a constraint i can be specified by m coefficients hij where (hi1, hi2, . . . , him) is
the “difference vector” Nkl in Eq. (2) (hij the jth element of the vector Nkl, corresponding to the
difference in the number of residues of amino acid type j).
Problem definition: Each of the n constraints can be written as
m∑
j=1
hij(cjxj +mj) = 0 (9)
where xj ∈ {0, 1}. Can we simultaneously satisfy all the constraints?
Claim 9 13C-omsep-sat is NP-hard.
Proof. The proof is by reduction from BIN FLS =. Assume WLOG that aij ∈ Z (i = 1, . . .n, j =
1, . . .m) (if not, multiply both sides of Eq. (8) by 1/q where q is the LCM of the denominators of the








Given such an instance of BIN FLS =, we create an instance of 13C-omsep-sat. Note that all mj





Now let’s look at our system of inequalities:
m∑
j=1
hij(cjxj +mj) = 0 i = 1, . . . , n.












































































so this system is just the system (8) scaled by (
∏
k ck), and so is satisfiable if and only if (8) is. Note
that we can add a set of dummy variables and set them to one to obtain the exact form of Lemma
8. If any rational coefficient ri − bi is non-integral, we can clear denominators by multiplying by one
over the LCM as described above.
If we let the largest number in the input be D, then the input to BIN FLS = is of size O(nm logD).
In our problem, the largest number can be as large as n!D, which means that the input is of size
O(nm(n logn+ logD), which is just a polynomial blowup.
Problem name: 13C-omsep
Input: Identical to 13C-omsep-sat. The constraints are again given in the form of Eq. (9).
Problem definition: Can we find a set of assignments xj ∈ {0, 1}, (j = 1, . . . , m) that minimizes the
number of unsatisfied constraints?
Lemma 1 13C-omsep is NP-complete.
Proof: NP-hardness follows directly from Claim 9. 13C-omsep is in NP because it is an instance of
the NP-problem Minimum Unsatisfying Linear Subsystem (muls) [5, 13, 7, 6, 8, 14, 3].
We have thus shown that the problem of determining whether a set of mass degeneracy constraints
is simultaneously satisfiable is NP-hard. Recall that each constraint is generated by a pair of fragment
hypotheses, and each fragment participates in many constraints. It is thus natural to ask whether there
exists a real protein that could actually generate exactly the constraints that arise in our reductions.
If we take the view that all pairs of fragments potentially interact, and we don’t know, a priori, which
ones will interact, then we cannot answer this question. If, on the other hand, as discussed in Sec. 1,
we assume we are given a priori binding-mode and -region hypotheses, the situation is different. In
this case we allow that we may not want to consider all pairs of fragments, due to other information.
Therefore we can construct a protein corresponding to the set of constraints. To do so, for each
constraint, we generate two fragments that will have the appropriate differences and will generate the
appropriate constraint. We then assume, in experiment planning, that none of these fragments will
interact with any other fragments except for designated pairs. Specifically, this requires adding a pair
of new fragments (and cleavage sites), for each i. The fragments are given by the difference vector Nkl
in Eq. (2), namely (hi1, hi2, . . . , him). Furthermore, this construction requires that our input set of a
priori hypotheses to the experiment planner ignore all pairwise fragment-fragment constraints except
for the correct ones in the reduction.
It is worth asking whether such a reduction is biologically relevant. It may be unlikely that such a
protein will be expressed naturally in the proteome of an organism. However, making such a protein is
certainly within the capability of standard biotechnology (where, given any de novo, designed primary
sequence, the techniques of standard recombinant DNA, protein overexpression, and purification can
be used to produce a sample). Until a distribution of ’hard’ vs. ’easy’ naturally occurring proteins
can be obtained, we feel the result of Lemma 1, which is realizable biotechnologically, provides insight
into the empirically observed combinatorial difficulty of the problem.
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